Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Thoracic malignancies 1

953 - Gene mutational profiling of Chinese EGFR-T790M mutation NSCLC patients required resistance to osimertinib by next generation sequencing (414O)

Date

17 Nov 2017

Session

Thoracic malignancies 1

Presenters

Chunwei Xu

Citation

Annals of Oncology (2017) 28 (suppl_10): x124-x143. 10.1093/annonc/mdx671

Authors

C. Xu1, W. Wang2, W. Zhuang3, Z. Song2, G. Lin3, X. Chen4, Y. Zhu5, M. Fang2, H. Zhang6, H. Wang7, J. Zhang8, Z. Yu9, R. Chen10, Y. Guan10, X. Yi10, Y. Chen1, G. Chen1, T. Lv11, Y. Song11

Author affiliations

  • 1 Pathology, Fujian Cancer Hospital, 350014 - Fuzhou/CN
  • 2 Chemotherapy, Zhejiang Cancer Hospital, 310022 - Hangzhou/CN
  • 3 Medical Oncology, Fujian Cancer Hospital, 350014 - Fuzhou/CN
  • 4 Thoracic Surgery, Fujian Cancer Hospital, 350014 - Fuzhou/CN
  • 5 Chest Disease Diagnosis And Treatment Center, Zhejiang Rongjun Hospital, 314000 - Jiaxing/CN
  • 6 Oncology, Xijing Hospital, the Fourth Milliatry Medical University, 710032 - Xi'an/CN
  • 7 Lung Cancer, Affiliated Hospital of Academy of Military Medical Science, 100071 - Beijing/CN
  • 8 Oncology, the Military General Hospital of Beijing, 100700 - Beijing/CN
  • 9 Oncology, Fuzhou General Hospital, Nanjing Military Area, 350025 - Fuzhou/CN
  • 10 -, Geneplus-Beijing, 1002200 - Beijing/CN
  • 11 Respiratory, Jinling Hospital, 210002 - Nanjing/CN
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 953

Background

Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), benefits patients with EGFR-T790M mutantion non-small-cell lung cancer (NSCLC) who fail treatment with first-generation EGFR TKIs. Identification of actionable genetic alterations conferring drug-resistance can be helpful for guiding the subsequent treatment decision. One of the major resistant mechanisms is EGFR-C797S mutation. Other mechanisms, such as MET amplifications and BRAF, and PIK3CA mutations, were also reported. In this study, we performed gene mutational profiling in a cohort of 117 EGFR-T790M NSCLC patients and acquired resistance to osimertinib using targeted NGS.

Methods

A total of 117 patients with stage IIIb-IV EGFR-T790M NSCLC were undergoing tumor biopsies, blood or serous effusions withdrawing by the time of acquiring resistance to osimertinib. We used targeted NGS to detect genes status of patients.

Results

In total, we identified 213 genetic alterations with a median of 4 mutations per patient. 58.12% (68/117) of patients still exhibit EGFR-T790M, 71.79% (84/117) of patients still exhibit EGFR sensitive mutations and 23.08% (27/117) of patients acquired EGFR-C797S mutations [Cis structure: 51.85% (14/27); Trans structure: 66.67% (18/27); Cis and trans structure coexistence: 18.52% (5/27)]. Besides other known resistance mechanisms, we identified MET amplification 16.24% (19/117) of patients, PIK3CA mutations in 10.26% (12/117) of patients, and KRAS mutations in 8.55% (10/117) of patients. Interestingly, we also observed TMPRSS2 and KIAA0226 mutations in EGFR-C797S/L718Q/L844V/L792F wild patients, which are restricted to osimertinib treatment resistance.

Conclusions

Our study uncovered mutational profiles of NSCLC patients with osimertinib resistance with potential therapeutic implications, and this study also is first study to depict the genetic landscapes comprehensively in Chinese NSCLC population resistant to osimertinib. Our analysis strongly suggests that MET amplification, PIK3CA mutations and KRAS mutations may serve as bypass resistance mechanisms in patients who are EGFR-C797S/L718Q/L844V/L792F wild type.

Clinical trial identification

Legal entity responsible for the study

Chunwei Xu

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.